ImmuPharma (LON:IMM) Stock Price Down 21.1% - Time to Sell?

Key Points

• ImmuPharma plc shares fell by 21.1% during mid-day trading, dropping to as low as GBX 10.80 ($0.15) after a closure at GBX 14.90 ($0.20).
• The company reported a negative P/E ratio of -1,446.18 and a predicted EPS of -339.0000022 for the current fiscal year.
• ImmuPharma specializes in developing peptide-based therapeutics, with their lead program being Lupuzor™, targeted at treating Lupus and potentially other autoimmune diseases.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) fell 21.1% on Thursday . The company traded as low as GBX 10.80 ($0.15) and last traded at GBX 11.76 ($0.16). 45,915,910 shares traded hands during trading, an increase of 438% from the average session volume of 8,530,393 shares. The stock had previously closed at GBX 14.90 ($0.20).

ImmuPharma Trading Up 5.7%

The firm has a market cap of £60.72 million, a PE ratio of -1,365.17 and a beta of 1.53. The stock has a fifty day simple moving average of GBX 4.07 and a two-hundred day simple moving average of GBX 3.21.

ImmuPharma (LON:IMM - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 131.41%. As a group, sell-side analysts predict that ImmuPharma plc will post -339.0000022 earnings per share for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.